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Abstract
Our objective was to assess the clinical effectiveness of shorter versus longer duration anti-
biotics for treatment of bacterial infections in adults and children in secondary care settings,
using the evidence from published systematic reviews. We conducted electronic searches
in MEDLINE, Embase, Cochrane, and Cinahl. Our primary outcome was clinical resolution.
The quality of included reviews was assessed using the AMSTAR criteria, and the quality of
the evidence was rated using the GRADE criteria. We included 6 systematic reviews (n =
3,162). Four reviews were rated high quality, and two of moderate quality. In adults, there
was no difference between shorter versus longer duration in clinical resolution rates for peri-
tonitis (RR 1.03, 95% CI 0.98 to 1.09, I2 = 0%), ventilator-associated pneumonia (RR 0.93;
95% CI 0.81 to 1.08, I2 = 24%), or acute pyelonephritis and septic UTI (clinical failure: RR
1.00, 95% CI 0.46 to 2.18). The quality of the evidence was very low to moderate. In chil-
dren, there was no difference in clinical resolution rates for pneumonia (RR 0.98, 95% CI
0.91 to 1.04, I2 = 48%), pyelonephritis (RR 0.95, 95% CI 0.88 to 1.04) and confirmed bacte-
rial meningitis (RR 1.02, 95% CI 0.93 to 1.11, I2 = 0%). The quality of the evidence was low
to moderate. In conclusion, there is currently a limited body of evidence to clearly assess the
clinical benefits of shorter versus longer duration antibiotics in secondary care. High quality
trials assessing strategies to shorten antibiotic treatment duration for bacterial infections in
secondary care settings should now be a priority.
Introduction
The UK government [1] and WHO [2] recognise that antimicrobial resistance is one of the
most important global public health threats that leads to mounting healthcare costs, treatment
failure, increased morbidity and excess deaths [2,3]. Antibiotic treatment rapidly selects for
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resistant bacterial strains in faecal [4] and nasal flora [5,6,7]. Resistance may persist for up to a
year [8] and is associated with risk of antibiotic-resistant infections [9,10], as is prior antibiotic
use [10,11]. At the population level lowering antibiotic consumption is associated with lower
rates of antibiotic resistance [12,13] and countries with higher antibiotic consumption tend to
have higher rates of antibiotic-resistant infections [14].
In primary care, reducing antibiotic consumption can be achieved safely by avoiding or
delaying prescriptions [15,16,17]. However, in secondary care patients with suspected bacterial
infection are likely to be more unwell, at greater risk of poor outcomes, and more likely to ben-
efit from antibiotic treatment [18,19]. If a patient has a life-threatening bacterial infection,
delays in administering effective antibiotics of even one hour increase mortality risk [20,21].
Efforts to avoid unnecessary deaths from life-threatening bacterial infection such as Red-Flag
Sepsis [22] and the new NICE sepsis guidelines [23] lower the bar for starting broad-spectrum
antibiotics in the first hours or days of a patient’s illness while diagnostic information becomes
available. Consequently strategies to reduce antibiotic overuse in secondary care focus on
decreasing the duration and breadth of spectrum of antibiotics after they have been started.
The UK Department of Health (DH) sets this approach out in its guidance ‘Start Smart then
Focus’ (SSTF) [24] which recommends all antibiotic prescriptions be reviewed and revised
after 24 to 72 hours with the aim of stopping or focusing treatment. However, this approach
may not successfully reduce unnecessary antibiotic use [25]. Among patients who turn out not
to need antibiotics, treatment may be continued as a result of ‘prescribing etiquette’, that is, cli-
nicians’ reluctance to modify prescribing decisions previously made by others [26]. Among
patients who do turn out to have a bacterial infection requiring antibiotics, recommended
durations of treatment are based almost entirely on historical precedent set at a time when the
dominant concern was under treatment rather than antibiotic overuse [27,28]. Clinical experi-
ence and research has progressively reduced recommended treatment [29,30] and an increas-
ing number of primary research studies and systematic reviews of studies suggest short
duration treatment may be sufficient to treat most bacterial infections. However, clinicians are
hampered because this evidence is fragmented and largely contained within condition-specific
reviews (e.g. meta-analyses in ventilator-associated pneumonia [31] and urosepsis [32]).
Overviews of systematic reviews involve the identification, retrieval, assessment and synthe-
ses of the evidence from multiple systematic reviews [33]. Such reviews provide a concise syn-
opsis of the evidence for research questions that have been addressed by systematic reviews,
provide clinicians, researchers and policy makers with a succinct summary of up-to-date evi-
dence from systematic reviews focussing on interventions for specific medical conditions, and
are useful for identifying areas that future research should focus on [1,34,35].
The objective of this systematic overview was therefore to critically appraise and summarize
the evidence from systematic reviews across a range of conditions comparing the effectiveness
and safety of short versus long duration antibiotic treatment for the clinical resolution of bac-
terial infections commonly encountered in secondary care settings.
Methods
We conducted electronic searches in the following databases: MEDLINE; Embase; Cochrane data-
base of review of effects (DARE); Cochrane database of systematic reviews; and Cinahl. Each data-
base was searched from inception until May 2016. No age or language restrictions were imposed.
The full search strategy and list of terms is in S1 Appendix. We hand searched the bibliography of
included studies to identify any other potential reviews. Where applicable, we contacted the corre-
sponding authors of included studies for additional information [see the review protocol at http://
www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42016046907].
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To be included in this overview, systematic reviews had to examine the clinical effectiveness
of short versus long duration treatment of bacterial infections in children or adults in second-
ary care settings. We excluded systematic reviews of infections routinely treated or restricted
to primary care and reviews of biomarker guided antibiotic therapy (because by design the
intervention arms do not have a fixed duration). We also excluded reviews of tuberculosis or
gastroenteritis. Studies comparing different classes of antibiotics, combination antibiotics, top-
ical antibiotics, delayed prescriptions, or high-dose short duration versus low- or normal-dose
long duration were also excluded.
Our primary outcome was clinical resolution as defined by the authors in the empirical
primary studies in included reviews (clinical success, clinical resolution, clinical failure, and
treatment failure). Secondary outcomes were microbiological cure, duration of symptoms,
complications, adverse events, development of new mono- or multi-drug resistant species,
development of antibiotic resistance, mortality, intensive therapy unit (ITU) admission and
patient adherence to therapy (including after treatment). Short durations of antibiotic treat-
ment were defined as single dose, one to three days, three to five days or five to seven days.
Long duration was defined as greater than seven days, but was reported according to the dura-
tion studied for comparison to shorter durations.
Two reviewers (IJO and JC) independently screened all titles and abstracts to determine eli-
gibility. Disagreements were resolved through discussion. Where both reviewers could not
reach an agreement, a third reviewer (CCB) arbitrated. Where two or more systematic reviews
were identified evaluating the same infection and with similar participants (e.g. two reviews on
UTI for children), we selected one review based on the following criteria (i) most direct rele-
vance to aim of this review, (ii) most recent and (iii) higher quality.
Where included reviews contained studies not comparing short versus long duration treat-
ment, we included only the trials comparing short versus long duration treatment for analysis.
Quality assessment was performed using the Assessment of Multiple Systematic Reviews
(AMSTAR) criteria [36] which examines 11 reporting domains of published reviews. The qual-
ity of the body of evidence across empirical studies in each included review (and for each out-
come) was presented as reported by that review. We reported the overall quality of included
primary studies in each review as rated by the review authors. Where an included review did
not report the quality of evidence across the included primary studies or for each relevant out-
come, we assessed the quality of the evidence using the Grading of Recommendation, Assess-
ment, Development and Evaluation (GRADE) criteria [37] which examines the domains of
study design, risk of bias, inconsistency, indirectness and imprecision. Three reviewers (IJO,
EAS and OAG) independently assessed the quality of included reviews and the overall quality
across included primary studies. Disagreements were resolved through discussion. Where
reviewers were unable to reach an agreement, a third reviewer (CCB) arbitrated.
Data extraction
Data were independently extracted by three reviewers (IJO, EAS, PST) onto customized
extraction sheets according to the characteristics of the included systematic reviews. These
included details about the study population, setting, diagnostic criteria, antibiotics used, short
and long dosing schedules, and primary and secondary outcome measures. For each infection
of interest, we used information from the source systematic review to extract data for each out-
come, the study population, number of trials and participants, relative effect sizes, and quality
of evidence.
We used risk ratios (RR) comparing short vs long durations with their corresponding 95%
confidence intervals (95% CI) to assess the effect of interventions for dichotomous data, and
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mean differences (MD) with their corresponding 95% CI for continuous data. If an included
review reported dichotomous outcomes using odds ratios (OR), we re-meta-analysed the data
using Review Manager (RevMan) Software version 5.3 [38] to convert the OR to RR and their
corresponding 95% CIs. When an included review included trials that did not meet the criteria
for a specific outcome, we re-meta-analysed the data by statistically pooling data only from the
relevant studies. I-square (I2) statistic was used to assess heterogeneity; values of 25%, 50% and
75% represented mild, moderate and substantial heterogeneity respectively. One reviewer
(IJO) entered the data into RevMan, and a second reviewer (EAS) independently checked the
data entry. Outcomes in adults and children were presented separately.
Results
Our searches identified 641 non-duplicate citations, of which 16 articles were eligible (Fig 1).
Ten articles were excluded because the report did not provide appropriate data for comparison
(n = 1) [39]; the comparison was intermittent versus continuous infusion (n = 2) [40,41]; dif-
ferent antibiotic combinations were compared (n = 1) [42]; not a conventional systematic
review (n = 1) [43]; antibiotics were compared with placebo or other interventions (n = 1)
[44]; reviews were older, less comprehensive reviews of other articles assessing the same condi-
tion that was included in the overview (n = 3) [45,46,47] and because the overall duration of
antibiotic therapy was similar across the intervention groups (n = 1) [48].
Six reviews [31,32,49,50,51,52] with a total of 3,162 participants were suitable for inclusion.
Three reviews included only adults, two included only children, and one included both adults
and children (Table 1). One included review [52] investigating short versus long duration
treatment for severe community-acquired pneumonia in children did not identify any primary
study for inclusion.
Primary studies in the included reviews were conducted in lower-middle- to high-income
settings (Table 1); however, one review [50] did not specify the setting where included primary
studies were conducted. The medical conditions examined in systematic reviews involving
adults included peritonitis, pyelonephritis, pneumonia and intra-amniotic infection. The con-
ditions assessed in systematic reviews involving children were bacteraemia, pneumonia and
bacterial meningitis. Five reviews defined their primary outcomes (Table 1), but only two
reported definitions of their secondary outcomes (S2 Appendix). Based on the AMSTAR crite-
ria, four reviews were rated high quality, and the remaining two were of moderate quality
(Table 1) [see S1 Table for scores of individual AMSTAR domains].
Shorter versus longer duration antibiotic treatment in adults
Peritonitis. We included one systematic review [50] that comprised three studies
(n = 230); two of the studies included patients with spontaneous bacterial peritonitis, while the
third study included patients with secondary peritonitis. The study settings were not reported.
Short and long duration therapies were three to five days and ten to 14 days respectively.
There was no significant difference in the rates of clinical cure between short versus long dura-
tion interventions: RR 1.03, 95% CI 0.98 to 1.09, I2 = 0% (Table 2; Fig 2A). The overall quality
of the evidence was graded as low. There were no significant differences between short versus
long duration therapy in the secondary outcomes of microbiological cure and survival (moder-
ate quality of evidence) (Table 3).
Pneumonia (non-ventilator-associated). We found one systematic review [50] that com-
prised three studies (n = 409). The study settings were not reported. Short and long duration
therapies were three to seven days and eight to 10 days respectively. There was no significant
difference in the rate of clinical cure between short versus long duration therapy: RR 1.01, 95%
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CI 0.92 to 1.10, I2 = 0% (Table 2; Fig 2A). The overall quality of the evidence was moderate.
There was no significant difference in microbiological cure in the one study that reported this
outcome: RR 1.16, 95% CI 0.89 to 1.51. The quality of evidence of this study was moderate
(Table 3).
Hospital-acquired pneumonia (ventilator-associated). We found one systematic review
[31] that included four studies (n = 472). The duration of antibiotic durations varied across the
studies depending on the antibiotic class investigated. The study settings ranged from lower-
Fig 1. Flow chart showing the process for inclusion of systematic reviews assessing shorter versus longer duration antibiotics for bacterial infections in
secondary care.
https://doi.org/10.1371/journal.pone.0194858.g001
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Table 1. Characteristics of included systematic reviews.
Study ID Population Studies
(Patients)
Countries
(World Bank
Criteriaa)
Diagnostic
criteria
Antibiotic
regimen
Definition of clinical
resolutionb
Overall
quality of
primary
studies
AMSTAR
ratingc
Havey 2011d [50] Hospitalized patients with
bacteremia or foci most
commonly associated with
bacteraemia (including
peritonitis, pyelonephritis,
pneumonia (non-
ventilator associated)
Bacteremia: 1 (69);
Peritonitis: 3 (240);
Pyelonephritis: 1
(80); Pneumonia: 6
(588)
Not specified Laboratory Same regimen;
different
duration
Not specified Low to
highi
Moderate
Karageorgopoulos
2009 [51]
Bacterial meningitis in
children
5 (426) USA, Greece,
Switzerland,
Chile, India
Clinical and
laboratory
Same regimen;
different
duration
Complete recovery or
substantial improvement of
symptoms and signs of
meningitis, of the per
protocol patients, at the
end-of-therapy evaluation
Lowj Moderate
Lassi 2015 [52] Severe community-
acquired pneumonia in
children 2–59 months
Nil Nil Clinical No restriction
on the type of
antibiotic;
different
duration
Improvement in
symptoms, such as return
of respiratory rate to the
normal age-specific range
and disappearance of chest
indrawing
N/A High
Pugh 2015 [31] Hospital-acquired
pneumonia in critically ill
adults (ventilator-
associated)
6 (1088) Severalg Clinical and
radiological
Different
duration
Resolution of clinical
features and improvement
or lack of progression of
radiographic response to
therapy; or lessening of
symptoms and signs of
infection such that
additional therapy is not
required
Low to
moderatek
High
Eliakim-Raz 2013
[32]
Acute pyelonephritis &
septic UTIe
2 (270) Spain,
Netherlands
Clinical and
laboratory
Different
duration
Resolution of fever or signs
and symptoms of UTI, or
antibiotic modification at
the end of the long-
treatment arm
Lowi High
Chapman 2014
[49]
Pregnant women with
intra-amniotic infectionf
2 (401) USA Clinical Same IV
antibiotic;
different
durationh
Treatment failure defined
as body temperature
reading after first
postpartum dose of
antibiotics, either once
above 39.0˚C or twice
above 38.4˚C, at 4 hours
apart (Edward 2003)
Lowk High
aWorld Bank historical classification by income (https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups)
bClinical resolution as originally defined in the review: this includes clinical success, clinical failure, or failure of treatment
cSee web appendix table 1 for individual domain ratings
d6/24 were pyelonephritis (2 were exclusively hospitalized adults); 1/24 was bacteremia in hospitalized neonates; 3/24 peritonitis (all in-hospital); 13/24 were pneumonia
(8 in exclusively hospitalized patients)
e3/8 studies exclusively in hospitals (one was different antibiotics)
fOnly 2/11 studies short versus long-course (Edwards 1993 & Chapman 1997)
gOne trial was an international multi-centre study conducted in 19 countries: Central and Southern America, Eastern Europe and Asia, and Western Europe, North
America and Australia
hAntibiotics administered to all subjects diagnosed with chorioamnionitis until delivery; participants in long duration group received antibiotics for at least 48 hours, or
until afebrile and asymptomatic for 24 hours
iBased on Cochrane risk of bias criteria. The quality rating for bacteremia was high, Peritonitis—low, Pyelonephritis–low, Pneumonia–low to moderate
jBased on Jadad criteria. Three studies had a score of 3, and two studies scored 2
kBased on GRADE rating [37]
https://doi.org/10.1371/journal.pone.0194858.t001
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Table 2. Comparison of effects of short and long duration of antibiotics in adults.
Condition Source
systematic
review
Primary Outcome Definition of
short vs long
duration
Studies
(#)
Patients
(#)
Relative effect of
short compared to
long duration
(risk measure
interpretation)
Quality of
the evidence
Antibiotics used
Peritonitis Havey 2011
[50]
Clinical cure 3–5 vs 10–14
days
3 230 RR 1.03, 95% CI 0.98
to 1.09, I2 = 0%,
P = 0.33
(no significant
difference)
Low1 Ertapenem; cefotaxime;
cefoperazone
Pneumonia (non-
ventilator-
associated)
Havey 2011
[50]
Clinical cure 3–7 vs 8–10
days
3 409 ΔRR 1.01, 95% CI
0.92 to 1.10, I2 = 0%,
P = 0.85
(no significant
difference)
Moderate2 Ceftriaxone; cefuroxime;
amoxicillin
Hospital-acquired
pneumonia
(ventilator-
associated)
Pugh 2015
[31]
Clinical
resolution
8+5 vs 15+5; 7
vs 10; 8 vs 12; 7
vs 16; 8 vs 15
4 472 ΔRR 0.93, 95% CI
0.81 to 1.08, I2 =
24%, P = 0.34
(no significant
difference)
Moderate3 Beta-lactam plus
aminoglycoside;
carbapenems†; various‡
Acute pyelonephritis
& septic UTI
Eliakim-Raz
2013 [32]
Clinical failure at
EOF
7 vs 14 days 1 236 RR 1.00, 95% CI 0.46
to 2.18, P = 1.00
(no significant
difference)
Moderate4 Ceftriaxone+cefixime;
fleroxacin
Clinical failure at
EOT
7 vs 28 days 1 34 RR 1.24, 95% CI 0.49
to 3.15, P = 0.64
(no significant
difference)
Very low5 Ampicillin or pivampicillin
Intra-amniotic
infection
Chapman
2014 [49]
Failure of
treatment (vaginal
delivery)
Single vs
multiple courses
of IV antibiotics
2 284 RR 1.46, 95% CI 0.39
to 5.51; I2 = 36%
(no significant
difference)
Moderate3 Single vs multiple dose
cefotetan (ampicillin and
gentamicin during labour
given to all women)
IV ampicillin and
gentamycin pre-labour vs
same regimen continued
post-delivery
Failure of
treatment (vaginal
delivery &
caesarean section)
Single vs
multiple courses
of IV antibiotics
1 292 RR 1.31, 95% CI 0.42
to 4.02, P = 0.64
(no significant
difference)
Low3 Single vs multiple dose
cefotetan (ampicillin and
gentamicin during labour
given to all women)
Success of
treatment
(caesarean
section)
1 117 RR 3.31, 95% CI 0.38
to 28.75, P = 0.28
(no significant
difference)
Low3 Single vs multiple dose
cefotetan (ampicillin and
gentamicin during labour
given to all women)
Abbreviations: EOF: end of follow-up; EOT: end of the long treatment arm; ROB: Risk of bias
single dose of cefotetan 2 g IV within 1 hour after delivery (short duration) vs cefotetan 2 g IV every 12 hours for a minimum of 48 hours (initial dose within 1 hour
after delivery) (long duration)
 IV ampicillin, 2 g every 6 hours, and gentamicin, 1.5 mg/kg every 8 hours (short duration) vs same regimen post-delivery until afebrile and asymptomatic for 24
hours (long duration)
†Doripenem 1g as 4-hour infusion 8 hourly for 7 days versus imipenem-cilastatin 1g as 1-hour infusion 8 hourly for 10 days
‡Cefoperazone- sulbactam, carbapenem and other third-generation cephalosporins; antibiotic combinations were used in 51% of cases
ΔRecalculated based on data from overall meta-analysis
1Study design: Not serious; ROB: Very serious; Inconsistency: Not serious; Imprecision: Not serious; Indirectness: Not serious
2Study design: Not serious; ROB: Serious; Inconsistency: Not serious; Imprecision: Not serious; Indirectness: Not serious
3Quality of evidence as reported from source systematic review using GRADE [37]
4Study design: Not serious; ROB: Serious; Inconsistency: N/A; Imprecision: Serious; Indirectness: Not serious
5Study design: Not serious; ROB: Very serious (open-label); Inconsistency: N/A; Imprecision: Serious; Indirectness: Not serious
https://doi.org/10.1371/journal.pone.0194858.t002
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middle- to high-income countries. There was no significant difference in the rates of clinical
resolution between short versus long duration antibiotic therapy: RR 0.93; 95% CI 0.81 to 1.08,
I2 = 24% (Table 2; Fig 2A). The overall quality of the evidence was moderate. No significant
differences were reported for any secondary outcomes except for 28-day antibiotic-free
days which favoured short durations: MD 4.02 days higher (2.26 to 5.78 higher); I2 = 68%;
P<0.00001, low quality of evidence; and the risk of subsequent infection due to resistant
Fig 2. Effect of shorter versus longer duration antibiotics on clinical resolution in adults with bacterial infection in secondary care.
https://doi.org/10.1371/journal.pone.0194858.g002
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Table 3. Secondary outcomes of systematic reviews in adults.
Condition Source
systematic
review
Secondary Outcome Definition of short vs
long duration
Studies
(#)
Patients
(#)
Relative effect of
short compared to
long duration
Risk measure
interpretation
Quality of the
evidence
Peritonitis Havey 2011
[50]
Microbiological cure 3–5 vs 5–14 2 154 RR 1.02, 95% CI
0.94 to 1.11, I2 =
0%, P = 0.66
No significant
difference
Moderate1
Survival 5 vs 10 days 2 140 RR 1.03 95% CI
0.97 to 1.10, I2 =
0%, P = 0.35
No significant
difference
Moderate2
Pneumonia (non-
ventilator-
associated)
Havey 2011
[50]
Microbiological cure 3 vs 8 days 1 45 RR 1.16 95% CI
0.89 to 1.51,
P = 0.28
No significant
difference
Moderate3
Pneumonia
(ventilator-
associated)
Pugh 2015
[31]
28-day mortality 8 vs 15 days, 7 vs 10
days, and 7 vs 16 days
3 598 †RR 1.11 95% CI
0.80 to 1.55, I2 =
0%, P = 0.53
No significant
difference
ModerateΔ
Recurrence of
pneumonia
8+5 vs 15+5 days; 7 vs
10 days; 8 vs 12 days; 7
vs 16 days; 8 vs 15
days
4 733 †RR 1.29, 95% CI
0.96 to 1.73, I2 =
5%, P = 0.09
No significant
difference
LowΔ
28-day antibiotic-free
days
8 vs 15 days, 7 vs 16
days
2 431 MD 4.02 days, 95%
CI 2.26 to 5.78, I2 =
68%, P <0.00001
Favors short
course
LowΔ
ITU mortality 7 vs 16 days, 8 vs 12
days
2 107 †RR 0.89, 95% CI
0.53 to 1.15, I2 =
0%, P = 0.67
No significant
difference
Low4
In-hospital mortality 8 vs 15 days 1 401 †RR 1.05, 95% CI
0.79 to 1.40, I2 =
0%, P = 0.74
No significant
difference
Low5
21-day mortality 8+5 vs 15+5 days 1 225 †RR1.04, 95% CI,
0.44 to 2.47,
P = 0.92
No significant
difference
Low6
60-day mortality 8 vs 15 days 1 401 †RR 0.90, 95% CI
0.65 to 1.23, I2 =
0%, P = 0.50
No significant
difference
Low7
90-day mortality 8+5 vs 15+5 days 1 198 †RR 0.99, 95% CI
0.56 to 1.74,
P = 0.97
No significant
difference
Low8
Relapse of pneumonia 8 vs 15 days, 8+5 vs 15
+5 days
2 626 †RR 1.55, 95% CI
0.97 to 2.46, I2 =
0%, P = 0.06
No significant
difference
Low9
Subsequent infection
due to resistant
organism
8 vs 15 days 1 110 †RR 0.68, 95% CI
0.47 to 0.98,
P = 0.04
Favors short
course
Moderate10
Duration of ICU stay 8 vs 15 days, 7 vs 16
days, 8+5 vs 15+5 days
3 656 MD 0.15 days, 95%
CI -1.00 to 1.29, I2
= 0%, P = 0.80
No significant
difference
Low11
Duration of hospital
stay
7 vs 16 days 1 30 MD -1.00 days, 95%
CI -4.11 to 2.11,
P = 0.53
No significant
difference
Low12
Duration of mechanical
ventilation
7 vs 16 days, 8 vs 12
days, 8+5 vs 15+5 days
1 30 MD 0.02 days, 95%
CI -0.51 to 0.54, I2
= 0%, P = 0.95
No significant
difference
Low13
Discontinuation
according to CPIS;
30-day mortality
3 days vs standard
course†
1 81 †RR 0.41, 95% CI
0.16 to 1.05,
P = 0.06
No significant
difference
Low14
Acute
pyelonephritis &
septic UTI
Eliakim-Raz
2013 [32]
Microbiological failure 7 vs 14 days 2 270 EOF: RR 0.92, 95%
CI 0.61 to 1.40, I2 =
0%, P = 0.70
No significant
difference
Low15
(Continued)
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organism which also favoured short duration treatment: RR 0.68, 95% CI 0.47 to 0.98, P = 0.04
(moderate quality of evidence) (Table 3).
Acute pyelonephritis and septic UTI. We included one systematic review [32] that com-
prised two RCTs; these compared intervention durations of seven versus 14 days and seven
versus 28 days, respectively. Both studies were conducted in high-income settings. There was
no significant difference in the risk of clinical failure between short versus long duration anti-
biotic therapy at the end of follow up in one RCT (n = 236): RR 1.00, 95% CI 0.46 to 2.18
(Table 2; Fig 2B). The quality of the evidence was moderate. The second study (n = 34)
reported no significant difference in the rates of clinical failure at the end of treatment between
groups: RR 1.24, 95% CI 0.49 to 3.15; however, the quality of the evidence was very low. There
was no significant difference in the secondary outcome of microbiological failure: RR 0.92,
95% CI 0.61 to 1.40, I2 = 0% (Table 3); the quality of the evidence was low.
Intra-amniotic infection (pregnancy-specific condition). We identified one systematic
review [49] that included two RCTs (n = 284) which met our inclusion criteria (Table 2). Both
studies were conducted in high-income settings. The studies compared single-dose versus
Table 3. (Continued)
Condition Source
systematic
review
Secondary Outcome Definition of short vs
long duration
Studies
(#)
Patients
(#)
Relative effect of
short compared to
long duration
Risk measure
interpretation
Quality of the
evidence
Intra-amniotic
infection
Chapman
2014 [49]
Infection-related
complications
Single vs multiple
courses of IV
antibiotics
1 292 RR 1.87, 95% CI
0.17 to 20.37,
P = 0.61 (wound
infection)
No significant
difference
LowΔ
Single vs multiple
courses of IV
antibiotics
1 292 RR 2.80, 95% CI
0.12 to 68.24,
P = 0.53 (pelvic
abscess)
No significant
difference
LowΔ
Duration of hospital
stay (days)
Single vs multiple
courses of IV
antibiotics
1 292 -0.9 days, 95% CI
-1.64 to -0.16,
P = 0.02
Favors short
course
ModerateΔ
Abbreviations: CPIS: Clinical Pulmonary Infection Score; EOF: End of follow-up; ITU: Intensive therapy unit; ICU: Intensive care unit; ROB: Risk of bias
IV ampicillin, 2 g every 6 hours, and gentamicin, 1.5 mg/kg every 8 hours vs same regimen post-delivery until afebrile and asymptomatic for 24 hours
ΔQuality rating as specified in the source systematic review (GRADE) [37]
†Further therapy after 3 days depended on the CPIS. The study was terminated because it was deemed “unethical”
1Study design: Not serious; ROB: Serious; Inconsistency: Not serious; Imprecision: Not serious; Indirectness: Not serious
2Study design: Not serious; ROB: Serious; Inconsistency: Not serious; Imprecision: Not serious; Indirectness: Not serious
3Study design: Not serious; ROB: Not serious; Inconsistency: N/A; Imprecision: Serious; Indirectness: Not serious
4Study design: Not serious; ROB: Serious; Inconsistency: Not serious; Imprecision: Serious; Indirectness: Not serious
5Study design: Not serious; ROB: Serious; Inconsistency: N/A; Imprecision: Serious; Indirectness: Not serious
6Study design: Not serious; ROB: Very serious; Inconsistency: N/A; Imprecision: Serious; Indirectness: Not serious
7Study design: Not serious; ROB: Serious; Inconsistency: Not serious; Imprecision: Serious; Indirectness: Not serious
8Study design: Not serious; ROB: Very serious; Inconsistency: N/A; Imprecision: Serious; Indirectness: Not serious
9Study design: Not serious; ROB: Serious; Inconsistency: Not serious; Imprecision: Serious; Indirectness: Not serious
10Study design: Not serious; ROB: Serious; Inconsistency: N/A; Imprecision: Not serious; Indirectness: Not serious
11Study design: Not serious; ROB: Very serious; Inconsistency: Not serious; Imprecision: Serious; Indirectness: Not serious
12Study design: Not serious; ROB: Very serious; Inconsistency: N/A; Imprecision: Serious; Indirectness: Not serious
13Study design: Not serious; ROB: Very serious; Inconsistency: Not serious; Imprecision: Serious; Indirectness: Not serious
14Study design: Not serious; ROB: Very serious; Inconsistency: N/A; Imprecision: Serious; Indirectness: Not serious
15Study design: Not serious; ROB: Very serious; Inconsistency: Not serious; Imprecision: Serious; Indirectness: Not serious
https://doi.org/10.1371/journal.pone.0194858.t003
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multiple-dose antibiotics, where multiple-dose was for a minimum of 48 hours or until partici-
pants were afebrile and asymptomatic for 24 hours. There was no significant difference in the
risk of treatment failure with vaginal delivery: RR 1.46, 95% CI 0.39 to 5.51; I2 = 36% (Fig 2B).
The quality of evidence was moderate. There was no significant difference in the risk of treat-
ment failure with caesarean section in one RCT (n = 117) that reported this outcome: RR 3.31,
95% CI 0.38 to 28.75; however, the quality of the evidence was low. There were no significant
differences in the secondary outcome of infection-related complications; the quality of evi-
dence was low (Table 3). However, the duration of hospitalisation was significantly shorter
with short duration treatment in the study that reported the outcome: MD -0.9 days, 95% CI
-1.64 to -0.16; the quality of evidence was moderate.
Shorter versus longer duration antibiotic therapy in children
Bacteraemia. We found one systematic review [50] that included one RCT (n = 66) which
compared seven- vs 14-day antibiotic treatment. The study settings were not reported. There
was no significant difference in the rates of clinical cure between short versus long duration
therapy: RR 0.88, 95% CI 0.75 to 1.02 (Table 4; Fig 3). The quality of evidence was moderate.
No secondary outcomes were reported.
Pneumonia. We found one systematic review [50] that included three RCTs (n = 253).
The study settings were not reported. Short antibiotic treatment duration was two to four
Table 4. Comparison of effects of short and long duration of antibiotics in children.
Condition Source systematic
review
Primary
Outcome
Definition of
short vs long
duration
Studies
(#)
Patients
(#)
Relative effect of short
versus long duration
(risk measure
interpretation)
Quality of the
evidence
Antibiotics used
Bacteremia Havey 2011 [50] Clinical
cure
7 vs 14 days 1 66 RR 0.88, 95% CI 0.75 to
1.02, P = 0.09
(no significant
difference)
Moderate1 Culture-directed
Pneumonia Havey 2011 [50] Clinical
cure
2–4 vs 4–7 days 3 253 †RR 0.98, 95% CI 0.91
to 1.04, I2 = 48%,
P = 0.48
(no significant
difference)
Low2 Ampicillin and
gentamicin (2);
Penicillin or cefuroxime
(1)
Pyelonephritis Havey 2011 [50] Clinical
cure
14 vs 21 days 1 80 RR 0.95 95% CI 0.88 to
1.04, P = 0.25
(no significant
difference)
Low3 Culture-directed
Bacterial
meningitis
Karageorgopoulos
2009 [51]
Clinical
success
4–7 days vs 7–14
days
5 383 ‡RR 1.02 95% CI 0.93 to
1.11, I2 = 0%, P = 0.70
(no significant
difference)
Moderate4 IV ceftriaxone
Abbreviation: ROB: Risk of bias
No primary studies were identified in one included systematic review [52]
†Data re-calculated using data from overall analysis
‡Data converted from OR to RR
1Study design: Not serious; ROB: Serious; Inconsistency: N/A; Imprecision: Not serious; Indirectness: Not serious (Chowdhary 2006)
2Study design: Not serious; ROB: Very serious; Inconsistency: Serious; Imprecision: Not serious; Indirectness: Not serious (Engle 2003; Engle 2000; Vuori-Holopainen
2000)
3Study design: Not serious; ROB: Very serious; Inconsistency: N/A; Imprecision: Not serious; Indirectness: Not serious (Cheng 2006)
4Study design: Not serious; ROB: Serious; Inconsistency: Not serious; Imprecision: Not serious; Indirectness: Not serious
https://doi.org/10.1371/journal.pone.0194858.t004
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days, while long duration was four to seven days. There was no significant difference in the
rates of clinical cure between short versus long duration therapy: RR 0.98, 95% CI 0.91 to 1.04,
I2 = 48%, (Table 4; Fig 3); however, the quality of evidence was low.
Pyelonephritis. We found one systematic review [50] that included one RCT (n = 80);
short and long duration therapy were 14 and 21 days respectively. The study setting was not
reported. There was no significant difference in the rates of clinical cure between groups: RR
0.95, 95% CI 0.88 to 1.04 (Table 4; Fig 3). The quality of evidence was low. There was a signifi-
cantly reduced rate of microbiological cure with short duration therapy in one study: RR 0.83,
95% CI 0.72 to 0.96, P = 0.01 (low quality of evidence) (Table 5).
Bacterial meningitis. We found one systematic review [51] that included five RCTs
(n = 383). The studies were conducted in lower-middle- to high-income settings. Antibiotic
therapy was four to seven days for short duration and seven to 14 days for long duration. The
bacterial organisms isolated were Neisseria meningitidis, Streptococcus pneumoniae, Haemophi-
lus influenzae or Streptococcus agalactiae. There was no significant difference in the rates of
clinical cure between groups: RR 1.02, 95% CI 0.93 to 1.11, I2 = 0% (Table 4; Fig 3). The quality
of evidence was moderate. There were no significant differences in the secondary outcomes of
Fig 3. Effect of shorter versus longer duration antibiotics on clinical resolution in children with bacterial infections in secondary care.
https://doi.org/10.1371/journal.pone.0194858.g003
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secondary nosocomial infections or persistence of CSF abnormalities (low quality evidence).
There were also no significant differences in the risk of adverse events, hearing impairment or
neurological complications–moderate quality of evidence (Table 5). However, the duration of
hospitalisation with significantly shorter with short duration antibiotic treatment: MD -2.95
days 95% CI -4.79 to -1.10, I2 = 0%, P = 0.002; the quality of evidence was moderate.
Discussion
Main findings. We found six systematic reviews including 26 randomised trials of 3,162
participants to include in this overview. The data show that, for adults in secondary care, there
was no difference in clinical resolution rates between short and long duration antibiotic ther-
apy for peritonitis, pneumonia, or acute pyelonephritis and septic UTI, based on 12 studies
Table 5. Secondary outcomes of systematic reviews in children.
Condition Source systematic
review
Secondary Outcome Definition of
short vs long
duration
Studies
(#)
Patients
(#)
Relative effect of
short versus long
duration
Risk measure
interpretation
Quality of the
evidence
Pyelonephritis Havey 2011 [50] Microbiological cure 14 vs 21 days 1 80 RR 0.83, 95% CI 0.72
to 0.96, P = 0.01
Favours longer
duration
Lowa
Bacterial
meningitis
Karageorgopoulos
2009 [51]
All-cause in-hospital
mortality
5 385 N/A
Persistence of CSF
abnormalities
(pleocytosis)
4–7 vs 8–14 days 1 52 †RR 5.00, 95% CI
0.63 to 39.91,
P = 0.13
No significant
difference
Lowb
Duration of
hospitalisation
7 vs 10 days 2 137 †MD: -2.95 days,
95% CI-4.79 to -1.10,
I2 = 0%, P = 0.002
Favours shorter
duration
Moderatec
Total adverse events 4–7 vs 10–14
days
2 122 †RR 1.16, 95% CI
0.71 to 1.87, I2 = 0%,
P = 0.56
No significant
difference
Moderated
Withdrawals due to
adverse events
NR or not observed
Secondary nosocomial
infections
7 vs 10 days 2 139 †RR 0.51, 95% CI
0.08 to 3.14, I2 =
75%, P = 0.47
No significant
difference
Lowe
Hearing impairment 4–7 vs 7–14 days 4 241 †RR: 0.74, 95% CI
0.41 to 1.32, I2 = 0%,
P = 0.31
No significant
difference
Moderatef
Long-term
neurological
complications
4–7 days vs 7–14
days
5 367 †RR 0.70, 95% CI
0.38 to 1.30, I2 = 0%,
P = 0.26
No significant
difference
Moderateg
Abbreviation: ROB: Risk of bias; NR: Not reported
No primary studies were identified in one included systematic review [52]
No suitable data for meta-analysis
aStudy design: Not serious; ROB: Very serious; Inconsistency: N/A; Imprecision: Not serious; Indirectness: Not serious
bStudy design: Not serious; ROB: Serious; Inconsistency: N/A; Imprecision: Serious; Indirectness; Not serious
cStudy design: Not serious; ROB: Serious; Inconsistency: Not serious; Imprecision: Not serious; Indirectness: Not serious
dStudy design: Not serious; ROB: Serious; Inconsistency: Not serious; Imprecision: Serious; Indirectness: Not serious
eStudy design: Not serious; ROB: Serious; Inconsistency: Very serious; Imprecision: Serious; Indirectness: Not serious
fStudy design: Not serious; ROB: Serious; Inconsistency: Not serious; Imprecision: Serious; Indirectness: Not serious
gStudy design: Not serious; ROB: Serious; Inconsistency: Not serious; Imprecision: Serious; Indirectness: Not serious
†Recalculated using data from source review
https://doi.org/10.1371/journal.pone.0194858.t005
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including 1381 randomised participants, of very low to moderate quality evidence. For intra-
amniotic infection there was very limited data of low to moderate quality (two trials including
292 participants) showing no difference in failure of treatment by antibiotic treatment dura-
tion. For children in secondary care, there was no difference in clinical resolution rate with
short versus long duration antibiotic therapy for bacteraemia, pneumonia, pyelonephritis and
bacterial meningitis, based on 10 studies of low to moderate quality including 782 randomised
participants.
For adults, duration of hospitalisation was significantly shorter in intra-amniotic infection
treated with short duration antibiotics. For other secondary outcomes including microbiolog-
ical cure rates in peritonitis, non-ventilator-associated pneumonia, acute pyelonephritis and
septic UTI, there were no important differences in secondary outcomes. For children, duration
of hospitalisation was significantly shortened with short duration antibiotics in bacterial men-
ingitis. There were no important differences in other secondary outcomes except for microbio-
logical cure rate which was significantly lower for short versus long treatment duration in
children with pyelonephritis.
Overall, there was a lack of evidence on the effect of duration of antibiotic therapy on devel-
opment of new mono- or multi-drug resistance, development of antibiotic resistance, or
patient adherence to therapy.
The included systematic reviews had moderate to high quality rating; however, the quality
of the overall body of evidence varied from low to high. The majority of published studies to
date have been conducted in high-income settings.
Comparison with the existing literature. We identified two overviews assessing the effect
of antibiotic treatment duration on clinical outcomes. In an overview of systematic reviews for
infections managed in outpatient settings [53], the authors found good evidence indicating
that shorter duration therapy was as effective as longer duration for most conditions. They
also found inadequate evidence about the effect of antibiotic duration on antibiotic resistance.
The findings in our overview are consistent with these.
In another rapid umbrella review of shorter versus longer term antibiotic therapy for man-
agement of community acquired pneumonia in adults in secondary care [54], the author con-
cluded that there was no significant difference in mortality rates; this is consistent with the
results of our overview. Although the author of the rapid review found no evidence on the
impact of antibiotic duration on duration of hospital stay, low quality evidence from our over-
view suggests that shortening antibiotic duration does not result in any significant impact on
the duration of hospital stay (see Table 3).
Comparison with existing guidelines. Our findings are partly supportive of current
NICE guidance for the management of hospital-acquired pneumonia in adults which specifies
5- to 10-days’ antibiotic therapy [55]; however, the results are not fully consistent with current
recommendations for management of moderate to severe pneumonia (seven to 10 days). Our
findings are also consistent with current American guidelines for the treatment of hospital-
acquired or ventilator-associated pneumonia [56]. NICE guidance specifies 7-day ciprofloxa-
cin therapy for patients with indwelling catheters (bladder, ureteric or nephrostomy) who
have pyelonephritis [57], and the evidence from existing reviews support this; however, NICE
specifies 14-day co-amoxiclav as an alternative but there is no research evidence cited for this
and other recommendations.
Our findings differ from current NICE guidance which recommends 10 and 14 days of
treatment for confirmed cases of H. influenzae and S. pneumoniae meningitis respectively [58].
Current American guidance recommends antibiotic duration from seven to>21 days depend-
ing on the infective organism isolated [59]. Though the evidence from our included systematic
review showed that short duration treatment was as effective as long duration treatment in
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children, the data from the included primary studies was insufficient to assess outcomes based
on causative organism.
Strengths and limitations. We searched extensively for systematic reviews across several
sources, and we accounted for the quality of the included reviews (AMSTAR) as well as the
overall quality of the evidence for each reported outcome (GRADE). However, our study has
some limitations. We may not have identified all relevant reviews assessing short versus long
duration antibiotic therapy in secondary care, especially unpublished articles. The variations
in the definitions of primary and secondary outcomes may have contributed to the high het-
erogeneity observed in some of the results. In some countries, e.g. the US, many facilities pro-
vide care that qualifies as primary and secondary care; in such settings patient populations
rather than settings may be more appropriate to assess the effect of antibiotic durations. In
addition, the outcome results for one included review [50] is limited to patients with blood-
stream infections. Overall there was little data and of variable quality, with insufficient or no
data on several important outcomes. Although this overview was aimed at providing targeted
audience (clinicians, microbiologists, researchers and policy makers) with up-to-date evi-
dence, some of the included reviews did not include up-to-date primary studies.
Implications for clinical practice. Currently, decision-making on duration of antibiotic
treatment in secondary care is hampered by a lack of evidence. The existing, limited evidence
we report here supports the use of short duration antibiotic treatment for adults, but more
data are needed to allow an evidence-based decision process. For children in secondary care
settings with bacteraemia, pneumonia, pyelonephritis or bacterial meningitis, short durations
of antibiotic therapy may attain similar rates of clinical success compared with long treatment
durations, but limited evidence suggests that long treatment significantly achieves greater rates
of microbiological cure in children with pyelonephritis. Short duration antibiotic treatment
results in significantly shorter durations of hospitalisation.
Implications for research and policy. We did not identify relevant systematic reviews for
several other important conditions generally managed in secondary care, including gastroin-
testinal/abdominal infections (except for peritonitis in adults), muscular infections, and bone
and soft tissue infections. New reviews comparing such interventions are required. Newer ran-
domised trials assessing short versus long duration antibiotics for treating bacterial infections
evaluated in some of the included reviews have been published (e.g. bacterial meningitis [60],
UTI [61]); consequently, the evidence for the conditions examined in those reviews needs
updating. Furthermore, one included review that assessed antibiotic duration of treatment for
pneumonia in children five years and under failed to identify any published primary study.
Therefore, randomised trials investigating such comparisons stratified by age (for pneumonia
and other childhood infections) should be conducted. Trials should be adequately powered,
well-reported, and should explicitly describe outcome definitions for their primary and sec-
ondary outcomes. With the exception of the included review on bacterial meningitis in chil-
dren [51], we were unable to synthesize the results on adverse events because of insufficient
data. This was largely due to inadequate reporting and description of adverse events in the pri-
mary studies of the included systematic reviews. Better reporting and description of harms in
future trials is therefore imperative.
None of the primary studies were conducted in a low-income setting; consequently, trials
investigating the effect of antibiotic durations on health outcomes in secondary care in low-
income settings should be encouraged.
Current guidelines need to be updated to reflect the current evidence base and the uncer-
tainty within it. For example, NICE guidelines for management of confirmed bacterial menin-
gitis in children recommends antibiotic treatment for 10–14 days in children three months
and older (H. influenzae or S. pneumoniae), and 14–21 days in children under three months
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(Group B streptococcus, Listeria monocytogenes, or Gram-negative bacilli) [58]; no research
document is cited for this guideline. However, the evidence base indicates that clinical out-
comes were equivalent when antibiotic therapy was given for four to seven days, compared to
longer durations. Future research should include an updated systematic review of all relevant
up-to-date studies to evaluate the outcomes of short versus long-term antibiotics in secondary
care to inform clinical practice.
Conclusions
There is currently a limited body of systematic review evidence including highly variable qual-
ity randomised trials, to clearly assess the balance of benefit to harm of short versus long dura-
tion antibiotic treatment for bacterial infections in secondary care. This limited evidence base
currently weakly supports short durations of antibiotic therapy for several conditions in adults
and in children, although there is also some evidence that short antibiotic treatments are less
effective than long durations at achieving microbiological cure for children with pyelonephri-
tis. The impact of antibiotic treatment duration on the development of drug resistance in sec-
ondary care requires further research. High quality randomised trials assessing strategies to
shorten antibiotic treatment duration for bacterial infections in secondary care settings should
now be a priority.
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